VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Core Insights - VolitionRx Limited has developed the Nu.Q® Vet Feline assay, achieving 100% specificity and detecting over 80% of feline lymphomas, marking a significant advancement in veterinary cancer diagnostics [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on early detection of diseases, including cancers, through blood tests [6][7] - The company aims to make cancer screening a routine part of annual wellness checks for pets, having already successfully rolled out a canine cancer test [3][6] Market Opportunity - The introduction of the feline cancer test could potentially double Volition's total addressable market in the companion animal space, as the canine test is already available in over 20 countries [4][5] - There are approximately 73.8 million pet cats in the U.S., with an estimated 1 in 5 cats likely to develop cancer in their lifetime, highlighting a significant market need [5] - The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster rate than the canine segment due to increasing owner awareness [5] Product Development and Revenue Potential - The successful publication of the study in a peer-reviewed journal is anticipated to unlock a $5 million contractual milestone payment for Volition [5] - The company is focused on completing product development and making the Nu.Q® Vet Feline Test available through existing distribution networks [3][4]